X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DR. REDDYS LAB - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DR. REDDYS LAB SUN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 24.8 24.1 103.3% View Chart
P/BV x 2.6 3.3 78.3% View Chart
Dividend Yield % 0.5 0.8 61.2%  

Financials

 SUN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
DR. REDDYS LAB
Mar-18
SUN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs7012,788 25.1%   
Low Rs4331,902 22.8%   
Sales per share (Unadj.) Rs110.4860.8 12.8%  
Earnings per share (Unadj.) Rs11.057.1 19.2%  
Cash flow per share (Unadj.) Rs17.2122.0 14.1%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.40.9 41.4%  
Book value per share (Unadj.) Rs158.8757.7 21.0%  
Shares outstanding (eoy) m2,399.26165.91 1,446.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x5.12.7 188.5%   
Avg P/E ratio x51.641.1 125.7%  
P/CF ratio (eoy) x32.919.2 171.2%  
Price / Book Value ratio x3.63.1 115.3%  
Dividend payout %18.235.0 52.0%   
Avg Mkt Cap Rs m1,360,021389,034 349.6%   
No. of employees `00017.823.5 75.6%   
Total wages/salary Rs m53,67132,149 166.9%   
Avg. sales/employee Rs Th14,890.96,070.8 245.3%   
Avg. wages/employee Rs Th3,017.11,366.6 220.8%   
Avg. net profit/employee Rs Th1,480.6402.5 367.9%   
INCOME DATA
Net Sales Rs m264,895142,810 185.5%  
Other income Rs m8,3881,552 540.4%   
Total revenues Rs m273,282144,362 189.3%   
Gross profit Rs m56,08123,512 238.5%  
Depreciation Rs m14,99810,772 139.2%   
Interest Rs m5,176788 656.8%   
Profit before tax Rs m44,29513,504 328.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 0.0%   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,4524,380 193.0%   
Profit after tax Rs m26,3389,468 278.2%  
Gross profit margin %21.216.5 128.6%  
Effective tax rate %19.132.4 58.8%   
Net profit margin %9.96.6 150.0%  
BALANCE SHEET DATA
Current assets Rs m316,359104,984 301.3%   
Current liabilities Rs m198,64368,938 288.1%   
Net working cap to sales %44.425.2 176.1%  
Current ratio x1.61.5 104.6%  
Inventory Days Days9574 127.5%  
Debtors Days Days108104 104.0%  
Net fixed assets Rs m213,178104,385 204.2%   
Share capital Rs m2,399830 289.1%   
"Free" reserves Rs m378,606124,886 303.2%   
Net worth Rs m381,006125,716 303.1%   
Long term debt Rs m17,72125,089 70.6%   
Total assets Rs m643,028225,443 285.2%  
Interest coverage x9.618.1 52.7%   
Debt to equity ratio x00.2 23.3%  
Sales to assets ratio x0.40.6 65.0%   
Return on assets %4.94.5 107.7%  
Return on equity %6.97.5 91.8%  
Return on capital %10.09.7 103.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m40,81672,623 56.2%   
Fx outflow Rs m30,14318,916 159.4%   
Net fx Rs m10,67353,707 19.9%   
CASH FLOW
From Operations Rs m39,07218,030 216.7%  
From Investments Rs m-33,708-14,883 226.5%  
From Financial Activity Rs m-15,393-4,440 346.7%  
Net Cashflow Rs m-7,359-1,236 595.4%  

Share Holding

Indian Promoters % 63.7 25.5 249.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 5.4 95.0%  
FIIs % 23.0 35.3 65.2%  
ADR/GDR % 0.0 18.5 -  
Free float % 8.3 15.3 54.2%  
Shareholders   133,026 75,885 175.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   NATCO PHARMA  PLETHICO PHARMA  WOCKHARDT LTD.  TORRENT PHARMA  PANACEA BIOTECH  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 146 Points Lower; IT and Power Stocks Drag(Closing)

Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.Sectoral indices ended on a mixed note with realty stocks.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS